▟ Vinebot intrinsic value, daily

← back

CAH Cardinal Health

healthcare · valued with opus medium conviction · deep-dived 2026-10-12

HOLD
Intrinsic value$118.10
Price (at call)$237.57
Margin of safety -50.3%
vs market (rating basis) -5.0%

Toll-booth oligopolist on US drug flow; specialty mix nudges thin margins up, priced near fair value.

The story

Cardinal Health is one of three US drug-distribution oligopolists alongside McKesson and Cencora. It moves about $250B of pharmaceuticals at razor-thin margins, but because the business runs on negative working capital it earns very high returns on capital. It is a mature franchise with a scale moat. Growth comes from GLP-1 and specialty volumes, oncology and MSO platforms, and higher-margin Optum/at-Home and Nuclear segments, while the Global Medical Products segment is a turnaround.

Reported margins of about 1% are depressed by opioid litigation and GMPS charges. The underlying adjusted margin is around 1.3% and is rising with the specialty mix, so I converge to 1.4% rather than lock in the trough GAAP figure. Sales-to-capital is trimmed from 42 to 30 to cover acquisitions such as the specialty MSO roll-ups. Near-term growth tracks the specialty and GLP-1 tailwinds and then fades to a nominal-GDP-like 3%.

Value drivers

Revenue growth (Y1)9.0%
Terminal growth3.0%
Forecast horizon8y
Target operating margin1.4%
Years to target margin4
Sales-to-capital6.00
Beta0.90
Failure probability2.0%
Cost of capital (WACC)8.7%
Terminal WACC9.1%

Valuation bridge

PV of explicit FCFF1.44B
PV of terminal value30.65B
Equity value27.35B
÷ shares → per share$118.10

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 277.13B 9.0% 1.1% 2.38B 3.81B -1.44B -1.32B
2 299.70B 8.1% 1.2% 2.81B 3.76B -950.01M -803.48M
3 321.53B 7.3% 1.3% 3.27B 3.64B -366.08M -284.73M
4 342.20B 6.4% 1.4% 3.76B 3.44B 312.31M 223.40M
5 361.27B 5.6% 1.4% 3.97B 3.18B 789.04M 519.05M
6 378.30B 4.7% 1.4% 4.15B 2.84B 1.32B 795.60M
7 392.89B 3.9% 1.4% 4.31B 2.43B 1.88B 1.05B
8 404.68B 3.0% 1.4% 4.44B 1.96B 2.48B 1.27B

Key risks

  • Drug pricing reform (IRA negotiation, PBM/340B changes) compresses distributor economics
  • Customer concentration: loss or repricing of a major account like the CVS/OptumRx type contracts
  • GLP-1 volume is low-margin and could shift to direct-to-consumer channels; ongoing opioid settlement payments

Catalysts

  • Specialty/MSO platform growth and continued upward EPS guidance revisions
  • GMPS margin recovery and potential separation of medical products

History

DatePriceIntrinsicMoSRating
2026-10-12$237.57 $118.10 -50.3% HOLD
2026-08-21$228.46 $49.39 -78.4% SELL
2026-07-01$237.56 $177.19 -25.4% BUY
2026-06-23$228.91 $66.52 -70.9% SELL